Abstract
Sepsis continues to be a major cause of morbidity, mortality, and post-recovery disability in patients with a wide range of non-infectious and infectious inflammatory disorders, including COVID-19. The clinical onset of sepsis is often marked by the explosive release into the extracellular fluids of a multiplicity of host-derived cytokines and other pro-inflammatory hormone-like messengers from endogenous sources (“cytokine storm”). In patients with sepsis, therapies to counter the pro-inflammatory torrent, even when administered early, typically fall short. The major focus of our proposed essay is to promote pre-clinical studies with hCG (human chorionic gonadotropin) as a potential anti-inflammatory therapy for sepsis.
Original language | English |
---|---|
Article number | 714177 |
Journal | Frontiers in Immunology |
Volume | 12 |
DOIs | |
State | Published - 13 Sep 2021 |
Bibliographical note
Publisher Copyright:© Copyright © 2021 Yoo, Mehdi, Pusapati, Mathur, Anipindi, Lunenfeld, Lowell, Yang, Metz, Khan, Leroith and Roth.
Funding
The authors declare that this study received philanthropic funding from Alan and Tatyana Forman through Altronix Inc. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.
Funders | Funder number |
---|---|
Altronix Inc. |
Keywords
- anti-inflammatory
- cytokine storm
- human chorionic gonadotrophic hormone (hCG)
- inflammation
- sepsis